The PPAR‐γ agonist rosiglitazone ameliorated the FS pathogenesis through the downregulation of  COX 1, IL‐1β, COL1, COL3, TNF‐α, vimentin, and α‐SMA. Here, VIM is linked to Feingold syndrome.